The prevalence of chronic kidney disease (CKD) is increasing due to the aging of the
population and multiplication of risk factors, such as hypertension, arteriosclerosis and …

Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …

Background Data on the safety of apixaban compared to warfarin in hemodialysis (HD)
patients are accumulating, but the impact of concomitant antiplatelet use is unknown …

Atrial fibrillation (AF) is associated with increased stroke and bleeding risk in patients with
chronic kidney disease (CKD). Little is known about the real-life use of non-vitamin K …

Background Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease
(ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of …

Objective Study on effect of risk factors on over-anticoagulation in patients taking
anticoagulant drugs with VKAs (vitamin K antagonists). Methods Cross-sectional descriptive …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) showed a benefit-risk
profile superior to that of warfarin in atrial fibrillation (AF) patients with mild to moderate …

Introduction: Apixaban is currently the only oral direct factor Xa inhibitor approved for
treatment and prevention of venous thromboembolism (VTE) in patients on hemodialysis …

Abstract Study Objective To compare bleeding and thromboembolic events in patients
receiving therapeutic doses of apixaban or rivaroxaban versus unfractionated heparin (UFH) …

Objectives: Research on effects of comorbidities disease on anticoagulation overdose in
patients receiving anticoagulant therapy with vitamin K antagonists anticoagulant (VKAs) …